Jed Kaminetsky, MD
Urology · Middle Village, NYNPI 1952378598
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Olympus America Inc. at 36.4% of the total. Reporting peaked in 2019 at $17,259 and has fallen 76.7% since, to $4,017 in 2025. Among urology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $252.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$13K
- Antares Pharma, Inc.$10K
- Clarus Therapeutics Inc.$4K
- Acerus Pharmaceuticals Corporation$3K
- Uroviu Corporation$2K
- Olympus Corporation Of The Americas$1K
- plus $3K from 28 others
Across 306 payments — averaging $11,295 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$2.1M
- AbbVie$475K
- Endo Pharmaceuticals Inc.$426K
- Siemens Medical Solutions USA, Inc.$81K
- Janssen Research & Development, LLC$60K
- Dendreon Pharmaceuticals LLC$49K
- plus $230K from 13 others
What the payments were for
- Consulting fees$17,42547%
- Speaking & faculty fees$7,22320%
- Travel & lodging$3,3909%
- Food & beverage$3,92711%
- Gifts$2,1786%
- Other$2,7167%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 25 | $13,417 |
| Antares Pharma, Inc. | 16 | $9,642 |
| Clarus Therapeutics Inc. | 5 | $4,007 |
| Acerus Pharmaceuticals Corporation | 9 | $3,427 |
| Uroviu Corporation | 2 | $2,100 |
| Olympus Corporation Of The Americas | 5 | $1,350 |
| Progenics Pharmaceuticals, Inc. | 6 | $441 |
| Johnson & Johnson | 5 | $327 |
| Astellas Pharma US Inc | 15 | $302 |
| Dendreon Pharmaceuticals LLC | 3 | $211 |
| Bioprotect Medical, Inc. | 3 | $175 |
| Urogen Pharma, Inc. | 6 | $174 |
| Pfizer | 7 | $156 |
| Tolmar, Inc. | 2 | $155 |
| Blue Earth Diagnostics | 1 | $145 |
| Boston Scientific | 5 | $128 |
| Immunitybio, Inc. | 4 | $123 |
| Dentsply IH AB | 3 | $62 |
| Novartis | 2 | $58 |
| Halozyme Inc | 2 | $48 |
| Merck | 2 | $48 |
| Bayer | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 1 | $39 |
| Verity Pharmaceuticals Inc. | 2 | $37 |
| Civco Medical Instruments | 1 | $36 |
| AbbVie(2 entities) | 2 | $33 |
| Laborie Medical Technologies Corp. | 1 | $31 |
| Aytu Biopharma, Inc. | 2 | $30 |
| Myriad Genetic Laboratories, Inc. | 2 | $28 |
| Dentsply IH Inc. | 1 | $25 |
| Coloplast | 1 | $17 |
| Neotract Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Metuchen Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JATENZO$12,154
- Olympus Resection Disposables$8,191
- XYOSTED$6,285
- Natesto$3,198
- NOCDURNA$3,000
- iTIND System$2,716
- Uro-G Flexible Cystoscope$2,100
- Erleada$266
- PYLARIFY$263
- PROVENGE$149
- Axumin$145
- ELIGARD$131
- BIOPROTECT BALLOON IMPLANT SYSTEM$130
How this compares
$36,859 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 121 | $84,143 |
| GemtesaVibegron | 98 | $69,255 |
| Dutasteride | 597 | $21,711 |
| Tamsulosin Hcl | 1,187 | $16,285 |
| Testosterone | 45 | $12,840 |
| Silodosin | 109 | $10,144 |
| Finasteride | 320 | $5,058 |
| Tadalafil | 34 | $4,866 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 192 | $4,471 |
| Potassium Citrate ErPotassium Citrate | 38 | $3,345 |
| Testosterone Cypionate | 47 | $2,553 |
| Cefpodoxime Proxetil | 50 | $1,409 |
| Solifenacin Succinate | 28 | $1,346 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $807 |
| Sildenafil Citrate | 56 | $761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $302 | $84,143121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.
Other urology in Middle Village
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.